HOME
ABOUT US 
ABOUT US

SSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs

Company Profile

Development History

Company Culture

Party Building

Video Center
INNOVATION 
INNOVATION

SSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.

Innovation and R&D

Information
PRODUCTS 
PRODUCTS

Respiratory System

Systemic Anti Infective Drugs

Digestive Tract And Metabolism

Cardiovascular System

Blood And Hematopoietic Organs

Medical Solution

Central Nervous System

Invigorate And Soothe The Nerves

Drug Substance

Medical Packaging Materials

Cosmetic Products
RECRUIT 
RECRUIT

It has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.

Talent Concept

Career Development

Social Recruitment

Campus Recruitment
SUBSIDIARIES 
SUBSIDIARIES

The company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.

Guangxiang Technology

Guangxiang Pharmaceutical

Guolong Pharmaceutical

Jiangsu Best

Hanlin Biotechnology
CONTACT 
CONTACT

We will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs

Contact us

Sales Network

Internal



LINK

OA E-mail EXCEL Server

中文/En

中文版

English

搜索





NEWS CENTER

Position:

Home

-

News Center

-

Announcement

2022.09.07

Polypropylene infusion bottle packaging metronidazole sodium chloride injection approved

After obtaining the approval documents for the production of Agatroban API and the first approved azithromycin dry suspension in China, Shijiazhuang No.4 Pharmaceutical Group achieved another success in product development.

2022.09.07

SJZ No.4 Pharmaceutical Agatroban API approved

Recently, Agatroban, which was declared by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang No.4 Pharmaceutical Group, was approved by the State Drug Administration to be registered as an API for listed preparations.

2022.09.05

Azithromycin dry suspension was approved for the first time in China

Recently, the azithromycin dry suspension developed by Shijiazhuang No.4 Pharmaceutical Co., Ltd. obtained the drug registration certificate issued by the State Drug Administration

SERVICE HOTLINE

400-616-8689

Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com

Mobile site

Wechat

E code

HOME

ABOUT US

INNOVATION

PRODUCTS

RECRUIT

SUBSIDIARIES

CONTACT

SEO TAG

CONTACT

MARKET

Power by 300.cn